Related Experiment Video

Updated: Jul 1, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.0K

Novel polymorphisms in CYP4A22 associated with susceptibility to coronary heart disease

Kang Huang1, Tianyi Ma1, Qiang Li1

  • 1Department of cardiovascular medicine, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, No. 43, Renmin Avenue, Haidian Island, 570100, Haikou, Hainan, China.

BMC Medical Genomics
|March 4, 2024
PubMed

Insights

Genetic variations in the CYP4A22 gene, specifically rs12564525 and rs2056900, are significantly associated with coronary heart disease (CHD) susceptibility in the Chinese Han population. These findings highlight potential genetic markers for CHD risk.

Area of Science:

  • Genetics
  • Cardiovascular Disease Epidemiology
  • Population Genetics

Background:

  • Coronary heart disease (CHD) is a global health concern.
  • Genetic factors play a crucial role in CHD development.
  • Investigating specific gene polymorphisms offers insights into CHD susceptibility.

Purpose of the Study:

  • To examine the association between CYP4A22 gene polymorphisms and CHD susceptibility.
  • To analyze genetic variations within the Chinese Han population.
  • To identify potential genetic risk factors for coronary heart disease.

Main Methods:

  • Case-control study involving 962 volunteers.
  • SNPStats and Haploview software for association and haplotype analysis.
  • Multi-factor dimensionality reduction (MDR) for SNP interaction evaluation.

Main Results:

  • CYP4A22-rs12564525 and CYP4A22-rs2056900 showed significant associations with CHD risk.
  • Stratified analyses revealed associations in specific subgroups (e.g., males, younger individuals, hypertensive patients).
  • The single-locus model of rs2056900 was identified as the best predictor for CHD susceptibility.

Conclusions:

  • Significant associations exist between CYP4A22 polymorphisms (rs12564525 and rs2056900) and CHD susceptibility.
  • These genetic markers may contribute to understanding the genetic basis of CHD.
  • Further research can explore the clinical implications of these findings.
Abstract

Keywords:
CYP4A22Chinese Han populationCoronary heart diseaseGenetic polymorphismSusceptibility

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.1K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.1K
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
17.7K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
91
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
137